Gene-guided repurposing identifies dihydroergotamine as a candidate inhibitor of the BCL2-SIVA1 axis in advanced gastric cancer in vitro.

Biol Direct · 2026 · PMC13224408 · PMID 41998706

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Although high BCL2 expression was not significantly associated with 5-year overall survival, it showed a nonsignificant trend toward worse 5-year survival (Fig. 2 C).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.